United States //   Endologix, Inc. to Announce Second Quarter 2019 Financial Results on August 8, 2019

Endologix, Inc. to Announce Second Quarter 2019 Financial Results on August 8, 2019

07/15/19

Endologix, Inc. to Announce Second Quarter 2019 Financial Results on August 8, 2019

IRVINE, Calif.--(BUSINESS WIRE)--Jul. 15, 2019-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2019 after the market close on Thursday, August 8, 2019. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

To participate in the conference call, dial 877-407-9716 (domestic) or +1 201-493-6779 (international) and refer to the passcode 13692632.

This conference call will also be webcast and can be accessed from the “Investors” section of the Company’s website at www.endologix.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 7:30 p.m. ET on Thursday, August 8, 2019, until 11:59 p.m. ET on Thursday, August 15, 2019. To hear this recording, dial 844-512-2921 (domestic) or +1 412-317-6671 (international) and enter the passcode 13692632.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once an AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. For more information, visit www.endologix.com.

Source: Endologix, Inc.

Investor:
Endologix, Inc.
Vaseem Mahboob, CFO
(949) 595-7200